PMID- 32030109
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1865-5025 (Print)
IS  - 1865-5033 (Electronic)
IS  - 1865-5025 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Feb
TI  - Synergistic Adhesiveness of Fibronectin with PHSRN Peptide in Gelatin Mixture 
      Promotes the Therapeutic Potential of Human ES-Derived MSCs.
PG  - 73-86
LID - 10.1007/s12195-019-00604-0 [doi]
AB  - INTRODUCTION: Mesenchymal stem cells (MSCs) are promising candidates for cell 
      therapy owing to their therapeutic effect in various diseases. In general, MSCs 
      grow efficiently in serum-containing culture media, indicating an essential role 
      of adhesion in their mesenchymal lineage-specific propagation. Nevertheless, the 
      use of non-human supplements in culture (xeno-free issue) in addition to the lack 
      of control over unknown factors in the serum hampers the clinical transition of 
      MSCs. METHODS: In this study, embryonic stem cell derived mesenchymal stem cells 
      (ES-MSCs) were used owing to their scalable production, and they expressed a 
      series of MSC markers same as adipose-derived MSCs. The affinity of the culture 
      matrix was increased by combining fibronectin coating with its adjuvant peptide, 
      gelatin, or both (FNGP) on tissue culture polystyrene to compare the 
      regenerative, therapeutic activities of ES-MSCs with a cell binding plate as a 
      commercial control. RESULTS: The FNGP culture plate promoted pivotal therapeutic 
      functions of ES-MSCs as evidenced by their increased stemness as well as 
      anti-inflammatory and proangiogenic effects in vitro. Indeed, after culturing on 
      the FNGP plates, ES-MSCs efficiently rescued the necrotic damages in mouse 
      ischemic hindlimb model. CONCLUSIONS: This study suggests a potential solution by 
      promoting the surface affinity of culture plates using a mixture of human 
      fibronectin and its adjuvant PHSRN peptide in gelatin. The FNGP plate is expected 
      to serve as an effective alternative for serum-free MSC expansion for bench to 
      clinical transition.
CI  - (c) Biomedical Engineering Society 2019.
FAU - Kim, Hye-Seon
AU  - Kim HS
AD  - Department of Medical Engineering, Yonsei University College of Medicine, Seoul, 
      03722 Republic of Korea. GRID: grid.15444.30. ISNI: 0000 0004 0470 5454
FAU - Choi, Sung Hyun
AU  - Choi SH
AD  - Cellular Therapeutics Team, Daewoong Pharmaceutical, Yongin, 17028 Gyeonggi-do 
      Republic of Korea. GRID: grid.454173.0. ISNI: 0000 0004 0647 1903
FAU - Kang, Mi-Lan
AU  - Kang ML
AD  - Department of Medical Engineering, Yonsei University College of Medicine, Seoul, 
      03722 Republic of Korea. GRID: grid.15444.30. ISNI: 0000 0004 0470 5454
FAU - Lee, Ki-Won
AU  - Lee KW
AD  - Department of Medical Engineering, Yonsei University College of Medicine, Seoul, 
      03722 Republic of Korea. GRID: grid.15444.30. ISNI: 0000 0004 0470 5454
FAU - Kim, Ki Nam
AU  - Kim KN
AD  - Cellular Therapeutics Team, Daewoong Pharmaceutical, Yongin, 17028 Gyeonggi-do 
      Republic of Korea. GRID: grid.454173.0. ISNI: 0000 0004 0647 1903
FAU - Sung, Hak-Joon
AU  - Sung HJ
AUID- ORCID: 0000-0003-2312-2484
AD  - Department of Medical Engineering, Yonsei University College of Medicine, Seoul, 
      03722 Republic of Korea. GRID: grid.15444.30. ISNI: 0000 0004 0470 5454
LA  - eng
PT  - Journal Article
DEP - 20191202
PL  - United States
TA  - Cell Mol Bioeng
JT  - Cellular and molecular bioengineering
JID - 101468590
PMC - PMC6981336
OTO - NOTNLM
OT  - ES-MSC
OT  - Fibronectin
OT  - Gelatin
OT  - PHSRN
OT  - Serum-free expansion
EDAT- 2020/02/08 06:00
MHDA- 2020/02/08 06:01
PMCR- 2020/12/02
CRDT- 2020/02/08 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2019/11/13 00:00 [accepted]
PHST- 2020/02/08 06:00 [entrez]
PHST- 2020/02/08 06:00 [pubmed]
PHST- 2020/02/08 06:01 [medline]
PHST- 2020/12/02 00:00 [pmc-release]
AID - 604 [pii]
AID - 10.1007/s12195-019-00604-0 [doi]
PST - epublish
SO  - Cell Mol Bioeng. 2019 Dec 2;13(1):73-86. doi: 10.1007/s12195-019-00604-0. 
      eCollection 2020 Feb.